Breaking News Instant updates and real-time market news.

CYCC

Cyclacel Pharmaceuticals

$3.94

-0.12 (-2.96%)

07:13
12/01/16
12/01
07:13
12/01/16
07:13

Cyclacel says data shows CYC140 therapeutic potential

Cyclacel Pharmaceuticals announced the presentation of preclinical data demonstrating the therapeutic potential of the Company's novel polo-like kinase, or PLK, 1 inhibitor, CYC140, as a targeted anti-cancer agent. The data demonstrates that CYC140 is a selective PLK1 inhibitor which preferentially induces growth inhibition and cell death in malignant versus non-malignant cells. The data were presented at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

CYCC Cyclacel Pharmaceuticals
$3.94

-0.12 (-2.96%)

08/12/16
HCWC
08/12/16
NO CHANGE
Target $60
HCWC
Buy
Cyclacel risk/reward positive ahead of AML study readout, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein said he recognizes that the small market cap of Cyclacel Pharmaceuticals keeps the stock from being appetizing to some investors, but he sees an "atypically positive risk/reward" ahead of its pending readout of a study in elderly acute myeloid leukemia patients unfit for induction therapy. An outright survival win in the study "may be a long shot," but the "surprise element" in AML can go both ways, Fein tells investors. Even without AML, Cyclacel is attractive based on its other two clinical programs, said the analyst, who has a $60 price target on the shares and thinks the stock could have a $173 per share full value if there were to be a topline win in AML.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.